HIT:NASDAQHealth In Tech, Inc. Analysis

Health In Tech (HIT) is trading at $0.92, well below its 20‑day SMA of $1.37, 50‑day SMA of $1.49, and 200‑day SMA of $1.98, indicating a strong bearish bias. The RSI of 25 signals oversold conditions, while the MACD histogram is negative and the signal line is marked bearish. A beta of 2.12 and 30‑day volatility above 100% point to extreme price swings, and the stock has experienced a historic max drawdown of roughly 75%.
On the fundamentals side, HIT posted $34.1 M in revenue with a 9.4% growth rate and projects $45‑$50 M for 2026, yet operating margins are negative (‑24.6%) and cash flow remains deeply negative. The balance sheet shows modest debt ($0.12 M) versus cash of $10.3 M, but free cash flow is a large outflow. A forward P/E of 6.44 is dramatically lower than the industry average of 39, suggesting cheap valuation, but the lack of earnings, negative cash generation, and high risk profile temper optimism.